This product has been prepared by Immunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other Apolipoproteins and human serum proteins to remove any unwanted specificities. Typically less than 1 % cross reactivity against other types of apoLipoprotein was detected by ELISA against purified standards. This antibody reacts with human Apolipoprotein E and has negligible cross-reactivity with Type A-1 A-II, B, C-I, C-II, C-III and J Apolipoproteins. Specific cross reaction of anti-Apolipoprotein antibodies with antigens from other species has not been determined. Non-specific cross reaction of anti-Apolipoprotein antibodies with other human serum proteins is negligible.
Purification
Immunoaffinity Chromatography
Immunogen
Apolipoprotein Type E was isolated from Human plasma by density gradient centrifugation followed by HPLC purification.
Anti-apoLipoprotein antibodies have been used for indirect trapping ELISA for quantitationof antigen in serum using a standard curve, for immunoprecipitation and for westernblotting for highly sensitive qualitative analysis. Recommended dilutions: ELISA: 1/4,000-1/8,000Western blot: 1/500-1/2,000Immunohistochemistry: 1/50-1/200 Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL (by UV absorbance at 280 nm)
Buffer
0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0, containing 0.01 % Sodium Azide as preservtive
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquts) at -20 °C for longer.
Apolipoprotein E is essential for the normal catabolism of triglyceride rich lipoprotein constituents. The apolipoprotein E gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in Apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Mutations in the APOE gene confer susceptibility to Alzheimer's disease by affecting amyloid-beta deposition.Synonyms: Apo-E, ApoE